ArticleMolecular medicine reports2020
Vitamin D receptor knockdown attenuates the antiproliferative, pro‑apoptotic and anti‑invasive effect of vitamin D by activating the Wnt/β‑catenin signaling pathway in papillary thyroid cancer.
Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vitamin D-Related Genes and Thyroid Cancer-A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Pre-diagnostic vitamin D deficiency and subsequent thyroid cancer risk: a propensity-matched cohort study.Frontiers in nutrition · 2026Article
- Vitamin D as a central modulator of thyroid diseases: mechanisms and clinical implications.Frontiers in immunology · 2026Review
- Reticuline and Coclaurine Exhibit Vitamin D Receptor-Dependent Anticancer and Pro-Apoptotic Activities in the Colorectal Cancer Cell Line HCT116.Current issues in molecular biology · 2025Article
- Vitamin D Deficiency and Its Role in Pathologies of Oxidative Stress: A Literature Review.Cureus · 2025Review
- Differential expression of cytokines and vitamin D in benign and malignant thyroid diseases.Scientific reports · 2025Article
- Recent Insights into the Roles of PEST-Containing Nuclear Protein.Molecular biotechnology · 2025Review
- Vitamin D receptor polymorphisms associate with the efficacy and toxicity of radioiodine-131 therapy in patients with differentiated thyroid cancer.Cancer biomarkers : section A of Disease markers · 2024Article
- Serum 25-hydroxyvitamin D level is unreliable as a risk factor and prognostic marker in papillary thyroid cancer.Annals of translational medicine · 2022Article
- Increased thyroid malignancy in patients with primary hyperparathyroidism.Endocrine connections · 2021Article
- Article
- Vitamin D Receptor Expression and its Clinical Significance in Papillary Thyroid Cancer.Technology in cancer research & treatmentArticle
- Vitamin D Status and VDR Polymorphisms as Prognostic Factors in Differentiated Thyroid Carcinoma.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin D and the vitamin D receptor (VDR) complex have been reported to inhibit the growth of several types of tumor; however, their function in papillary thyroid cancer (PCT) remains unknown. In addition, the Wnt/β‑catenin signaling pathway was discovered to serve a critical role in the pathology of PCT. Therefore, the present study aimed to determine the role of the VDR and its association with Wnt/β‑catenin signaling in vitamin D‑treated PTC cells. VDR expression was detected in human PTC cells (including MDA‑T120, MDA‑T85, SNU‑790 and IHH4 cells) and thyroid follicular cells (Nthy‑ori 3‑1 cells). SNU‑790 and IHH4 cells were infected with KD‑VDR or negative control (KD‑NC) lentiviruses, treated with 1,25(OH)2D3 (the active form of vitamin D), and subsequently referred to as the KD‑VDR&vitD and KD‑NC&vitD groups, respectively. Additionally, PTC cells infected with KD‑NC and not treated with 1,25(OH)2D3 were used as the normal control and referred to as the KD‑NC group. VDR mRNA and protein expression levels were increased in MDA‑T120, SNU‑790 and MDA‑T85 cells compared to Nthy‑ori 3‑1 cells, whereas in IHH4 cells, VDR mRNA and protein expression levels were similar to Nthy‑ori 3‑1 cells. In SNU‑790 and IHH4 cells, cell proliferation and invasion were decreased in the KD‑NC&vitD group compared with the KD‑NC group, but increased in the KD‑VDR&vitD group compared with the KD‑NC&vitD group. Cell apoptosis was increased in the KD‑NC&vitD group compared with the KD‑NC group, and decreased in the KD‑VDR&vitD group compared with the KD‑NC&vitD group. Furthermore, the expression levels of Wnt family member 3 and catenin β1 were decreased in the KD‑NC&vitD group compared with the KD‑NC group, but increased in the KD‑VDR&vitD group compared with the KD‑NC&vitD group. In conclusion, the present study revealed that VDR‑KD attenuated the antiproliferative, pro‑apoptotic and anti‑invasive effects of vitamin D in PTC by activating the Wnt/β‑catenin signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.